Immunome (NASDAQ:IMNM) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a report issued on Friday,RTT News reports. They currently have a $21.00 price target on the stock.

IMNM has been the topic of several other reports. Craig Hallum assumed coverage on shares of Immunome in a report on Friday, September 5th. They set a “buy” rating and a $26.00 price objective on the stock. Guggenheim reissued a “buy” rating and issued a $25.00 price target on shares of Immunome in a research report on Monday, August 25th. JPMorgan Chase & Co. dropped their price target on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. The Goldman Sachs Group initiated coverage on shares of Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 price objective for the company. Finally, Evercore ISI initiated coverage on Immunome in a research report on Friday, August 22nd. They set an “outperform” rating and a $18.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.20.

Immunome Stock Performance

NASDAQ IMNM traded down $0.26 on Friday, hitting $15.24. 1,665,412 shares of the stock traded hands, compared to its average volume of 1,235,020. The business’s fifty day moving average is $12.83 and its two-hundred day moving average is $10.48. Immunome has a 12 month low of $5.15 and a 12 month high of $17.87. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -5.17 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 77.37%. Analysts expect that Immunome will post -2.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IMNM. Assetmark Inc. bought a new position in shares of Immunome in the third quarter worth $39,000. BNP Paribas Financial Markets grew its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Immunome in the 1st quarter valued at about $95,000. Finally, Brighton Jones LLC purchased a new stake in shares of Immunome in the 2nd quarter valued at about $98,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.